Novo Nordisk's Strategic Partnership with Valo Health to Revolutionize Cardiometabolic Treatments

Novo Nordisk has entered into a partnership with Valo Health, a machine learning and drug discovery startup, to expand its cardiometabolic pipeline. In exchange for $60 million upfront and near-term payments, Novo will gain access to three cardiovascular assets developed by Valo. The deal also includes the potential for milestone payments of up to $2.7 billion for additional programs, as well as funding for R&D and potential royalties.